Lab developer Alexandria Real Estate Partners will sell the Moderna Technology Center in Norwood to the vaccine manufacturer for approximately $400 million as it continues to divest non-core properties in Greater Boston.
Massachusetts lost biomanufacturing jobs last year, raising questions about the sector’s future in the state. But local and state leaders are planning initiatives to show the Bay State remains a formidable powerhouse.
Moderna will open a new 140,000-square-foot biomanufacturing plant next year that’s being developed by Oxford Properties Group on a 24-acre site.
A 500,000-square-foot life science tower under construction in the Fenway has serious interest from tenants for 84 percent of the building just three months after its acquisition by Alexandria Real Estate Equities.
Life science specialist Alexandria Real Estate Equities has acquired a 54-acre Norwood property with potential for additional commercial development for $105 million.
Cambridge-based Moderna plans on Monday to request emergency use authorization of its COVID-19 vaccine from the U.S. Food and Drug Administration and the European Medicines Agency.
Cambridge-based pharmaceutical company Moderna said Monday its COVID-19 vaccine is proving to be highly effective in a major trial, a second dash of hope in the global race for a shot to tame a resurgent virus that is now killing more than 8,000 people a day worldwide.
Despite its position on the leading edge of medical research, Massachusetts is probably no better prepared to deal with a mass epidemic than many other places around the country.
If we get hit with anything like what we have seen from afar in China, there will be major disruptions to every facet of life, including businesses.
